Literature DB >> 8935256

Drug treatment in Switzerland: harm reduction, decentralization and community response.

H K Klingemann1.   

Abstract

This paper first outlines the history of illicit drug issues in Switzerland, and then describes drug treatment services and shifts in treatment concepts. In the last 15 years the drug treatment system in Switzerland has expanded considerably. In particular there has been an unprecedented growth of the non-residential sector and of low-threshold programmes, including methadone treatment, the establishment of injection rooms and controlled drug-prescription pilot projects. In the second part, the paper considers some selected factors that promote or impede changes in drug treatment systems, such as treatment policy and the public response to treatment measures. This is manifested in the influence of community action groups on local programme development.

Entities:  

Mesh:

Substances:

Year:  1996        PMID: 8935256     DOI: 10.1046/j.1360-0443.1996.9157238.x

Source DB:  PubMed          Journal:  Addiction        ISSN: 0965-2140            Impact factor:   6.526


  10 in total

1.  Safe injection facilities in Canada: is it time?

Authors:  T Kerr; A Palepu
Journal:  CMAJ       Date:  2001-08-21       Impact factor: 8.262

2.  Policy progress for physician treatment of opiate addiction.

Authors:  Joseph O Merrill
Journal:  J Gen Intern Med       Date:  2002-05       Impact factor: 5.128

3.  Mexico's drug policy reform: cutting edge success or crisis in the making?

Authors:  Dan Werb; María Elena Medina Mora; Leo Beletsky; Claudia Rafful; Tim Mackey; Jaime Arredondo; Steffanie A Strathdee
Journal:  Int J Drug Policy       Date:  2014-06-02

4.  Open drug scenes: responses of five European cities.

Authors:  Helge Waal; Thomas Clausen; Linn Gjersing; Michael Gossop
Journal:  BMC Public Health       Date:  2014-08-16       Impact factor: 3.295

5.  Ethnic- and gender-specific differences in the prevalence of HIV among patients in opioid maintenance treatment-a case register analysis.

Authors:  Michael Liebrenz; Rudolf Stohler; Carlos Nordt
Journal:  Harm Reduct J       Date:  2014-08-18

6.  The Accessibility of Opioid Agonist Treatment and Its Forced Discontinuation in Swiss Prisons-Attitudes, Perceptions and Experiences of Defense Lawyers in Dealing With Detained Persons Using Opioids.

Authors:  Anna Buadze; Stephanie Baggio; Roman Schleifer; Eveline Aeberhard; Hans Wolff; Andres Schneeberger; Michael Liebrenz
Journal:  Front Psychiatry       Date:  2020-05-14       Impact factor: 4.157

7.  Successes and failures in treatment of substance abuse: Treatment system perspectives and lessons from the European continent.

Authors:  Harald Klingemann
Journal:  Nordisk Alkohol Nark       Date:  2020-08-17

8.  Patterns, determinants and barriers of health and social service utilization among young urban crack users in Brazil.

Authors:  Marcelo Santos Cruz; Tarcisio Andrade; Francisco I Bastos; Erotildes Leal; Neilane Bertoni; Lara Lipman; Chantal Burnett; Benedikt Fischer
Journal:  BMC Health Serv Res       Date:  2013-12-28       Impact factor: 2.655

9.  High-Dose Benzodiazepine Dependence: A Qualitative Study of Patients' Perceptions on Initiation, Reasons for Use, and Obtainment.

Authors:  Michael Liebrenz; Marcel Schneider; Anna Buadze; Marie-Therese Gehring; Anish Dube; Carlo Caflisch
Journal:  PLoS One       Date:  2015-11-10       Impact factor: 3.240

10.  Fifteen years of heroin-assisted treatment in a Swiss prison-a retrospective cohort study.

Authors:  Michael Liebrenz; Alex Gamma; Anna Buadze; Roman Schleifer; Stéphanie Baggio; Bruce Schwartz; Andres Schneeberger; Ambros Uchtenhagen
Journal:  Harm Reduct J       Date:  2020-10-13
  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.